Pamplona, Spain November 6, 2023  Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, for the treatment of patients with Prader-Willi Syndrome (PWS)....